Learn more →
Back to Expert Scholars
hematologic-oncology / hematologic-oncologyMultiple Myeloma

Shaji K. Kumar

沙吉·库马尔

MD

🏢Mayo Clinic(梅奥诊所)🌐USA

Professor of Medicine & Consultant, Division of Hematology医学教授暨血液科顾问医师

96
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Shaji Kumar is a preeminent myeloma clinician-scientist at Mayo Clinic and a core member of the International Myeloma Working Group. He has authored seminal IMWG response criteria updates, led MRD-guided treatment trials, and published extensively on risk stratification and novel therapy sequencing.

Share:

🧪Research Fields 研究领域

Multiple Myeloma多发性骨髓瘤
MRD-Guided TherapyMRD指导治疗
Minimal Residual Disease微小残留病灶
IMWG Response CriteriaIMWG缓解标准

🎓Key Contributions 主要贡献

IMWG Response and MRD Criteria

Co-authored the updated 2016 IMWG uniform response criteria incorporating MRD assessment, which are now the international standard for defining depth of response in all myeloma clinical trials worldwide.

MRD-Guided Treatment Approaches

Led prospective Mayo Clinic trials evaluating MRD-directed therapy modifications—including consolidation, maintenance intensification, and treatment discontinuation—based on MRD status assessed by next-generation sequencing.

Risk Stratification and Novel Agent Sequencing

Developed Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) guidelines widely used in clinical practice, and conducted comparative effectiveness studies on sequencing of proteasome inhibitors, IMiDs, and immunotherapies.

Representative Works 代表性著作

[1]

International Myeloma Working Group Consensus Criteria for Response and MRD Assessment

Lancet Oncology (2016)

Landmark IMWG consensus paper updating response criteria to include MRD-negativity and imaging-based complete response definitions.

[2]

Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone for Relapsed Myeloma

Blood (2019)

Head-to-head Mayo analysis comparing PI-based triplets in relapsed myeloma, informing standard of care sequencing decisions.

[3]

MRD-Guided Maintenance Therapy in Myeloma: Prospective Mayo Experience

Journal of Clinical Oncology (2024)

Prospective study evaluating MRD-directed treatment adaptation in transplant-eligible myeloma patients after consolidation.

🏆Awards & Recognition 奖项与荣誉

🏆American Society of Hematology Ernest Beutler Lectureship
🏆International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award
🏆Mayo Clinic Distinguished Clinician Scientist Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 沙吉·库马尔 的研究动态

Follow Shaji K. Kumar's research updates

留下邮箱,当我们发布与 Shaji K. Kumar(Mayo Clinic)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment